Innovation strategies for the Australian chemical industry by Upstill, G. (Garrett) et al.
      Journal of Business Chemistry Vol. 3, Issue 3 September 2006 
 
 
© 2006 Institute of Business Administration                                 ISSN 1613 – 9615 
 www.businesschemistry.org
 
 
 
 
 
Research Paper 
 
 
Innovation Strategies for the Australian Chemical Industry 
 
 
Garrett Upstill*#, Alan J. Jones**#, Tom Spurling*** and Greg Simpson**** 
 
* School of Business, University of New South Wales (ADFA Campus), Canberra, ACT 2600, Australia. 
** Visiting Fellow, National Graduate School of Management, College of Business and Economics, Australian Na-
tional University, ACT 2601 and Adjunct Professor of Innovation, Management and Performance Management in 
the Division of Business, Law and Information Sciences, University of Canberra, Australia. 
*** Australian Centre for Emerging Technologies and Society, Swinburne University of Technology, PO Box 218, 
Hawthorn, Victoria 3122, Australia. 
**** CSIRO Division of Molecular and Health Technologies, Private Bag 10, Clayton South, Melbourne, VIC 3169, 
Australia.  
#   Correspondence to: alan.jones@anu.edu.au or g.upstill@adfa.edu.au. 
 
 
 
 
 
 
 
Abstract:  The Australian chemical industry is facing a testing period as it adjusts to the challenges of the 
new global era. This paper briefly traces the evolution of the industry through an extended period behind 
protective tariff barriers to the situation today, as it confronts the new competitive environment. While the 
industry is adjusting as new companies emerge and specialist export-oriented production increases, the cur-
rent situation continues as “work in progress”. We argue that its future success will depend on its ability to 
innovate and to renew itself. We draw some generic lessons from a review of successful innovation in the 
Australian chemical industry and identify four key strategies for companies namely: (1) working within exist-
ing global value chains, (2) engaging with other globally focused industries, (3) developing an integrated pack-
aging concept for their products and services, and (4) leveraging the knowledge of others. 
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Introduction 
The central role of the chemical industry in the 
economic and social fabric of most advanced 
economies has been demonstrated over the past 
150 years. Over that time the industry has been 
continuously transformed by the introduction of 
product and process innovations largely driven by 
research and development conducted by corpora-
tions, universities and national laboratories. The 
industry produces over 70,000 different chemical 
substances valued at over USD 1.5 trillion per an-
num [1]. In more recent times the industry has 
faced some serious problems with the evolution of 
global markets, the growth in regulatory controls, 
the slowing down of innovation as exhibited in 
diminishing returns to R&D, and skills shortages 
[2]. 
Arora et al. have highlighted the role of science 
in the productivity and growth of the chemical in-
dustry in Europe, the United States and Japan [3], 
the changes in the industry brought about by li-
censing of patent protected technology [4], the 
changing division of labour and emerging markets 
for technology in the chemical industry [5]. Arora 
et al. described the massive restructuring that took 
place in the US chemical industry in the 1980’s 
(well in advance of Europe or Japan) and which 
contributed to improved results in many US 
chemical firms. In particular, these authors noted 
the division of “innovative” labour and the devel-
opment of wide networks of collaboration preva-
lent in the new and emerging areas of the chemical 
industry in contrast to the activities of the large-
scale basic ‘commodities-type’ chemical industry. 
Both of these factors are important as the Austra-
lian chemical industry makes readjustments to 
market deregulation. In addition to the work of 
Arora et al., other literature has also addressed the 
importance of large scale production [6], and the 
increasing rise of licensing activity [7]. Very re-
cently, Swift [8] reviewed the near-term business 
environment in which the world industry will op-
erate and the prospects and challenges to be faced 
in 2006 and 2007. 
In addition, there have been a number of re-
ports addressing some of the problems facing the 
industry at the level of national concern: 
 
• In the European Union [9, 10] the frequency 
for innovative opportunities has been a major 
concern along with the issue of the number of 
newly banned chemicals. Harries-Rees [11] has 
suggested that there has been a shift towards 
short- and medium-term customer and market 
driven incremental changes in products and 
processes in the European industry, with 
higher risk longer-term activities have been 
handled in a variety of individualistic ways in 
different companies – motivated by “getting 
the balance right” between the short/medium- 
and long-term activities. In addition, interna-
tional collaboration at the research level, and 
the movement of people and ideas within the 
industry, has occurred [11]. 
• In the USA two reviews [12, 13], and the es-
tablishment of the industry-led Chemistry In-
dustry Vision 2020 [14] with a strong emphasis 
on energy efficiency and protection of the en-
vironment and more recently on environ-
mental and health impacts of nano-materials 
[15]. 
• In the UK [16], Japan [17], and Denmark 
[18], where energy savings emerge as a princi-
ple issue. 
Whatever the commentary, the fact is that each 
company working in the chemical industry must 
chart its own innovation strategy in such a way 
that exploits its key strengths and the opportuni-
ties that are available to it. This may take a variety 
of forms. Innovation may be technological – in the 
form of new products, or processes - or non-
technological – e. g., in the form of new services 
or organisational arrangements as described by 
Tidd et al. [19]. Moreover, increasingly it is likely 
to involve others outside the company for ways to 
develop and exploit ideas, as Chesborough con-
vincingly argues [20]. Nonetheless, the envelope of 
strategies that are available for countries will differ 
according to different national innovation systems, 
including consideration of the nations’ resource 
endowments, the company base and the links with 
international companies, and the particular regula-
tory settings in which they function. 
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What is the Chemical Industry? 
We follow a structure of the chemical industry 
as defined by the international Standard Industry 
Classification (SIC) codes, which are used for data 
collection on the industry. Although the code sys-
tems used from nation to nation are marginally dif-
ferent, in general, the chemical industry embraces 
the manufacture of basic chemicals (including 
chemicals derived from coal and/or oil), other 
chemical products (including medicinal and phar-
maceutical products), rubber and plastic (or poly-
mer) products. In most cases the industry includes 
all products derived from petroleum refining [21]. 
We have also included consideration of biotech-
nology since much of the activity in this area in 
Australia is directed towards R&D on pharmaceu-
ticals. 
Impact of Change on the Australian 
Chemical Industry 
The Australian chemical industry has also faced 
testing times in confronting the challenges posed 
by globalisation and the changing patterns of pro-
duction and trade. Even though the Australian in-
dustry is enmeshed with the global chemical indus-
try, its companies face a different set of challenges 
and opportunities. In particular it needs to rethink 
its prospects, and the role of innovation. For many 
years the industry was protected from external 
competition by high tariff barriers and restrictions 
to trade. With the liberalisation of world markets 
and the substantial lowering of tariffs, the future 
success of the industry in Australia will depend on 
its capacity to change through innovation, to in-
troduce competitive new and innovative products, 
processes and services, and meet the demands of 
both existing and new markets. 
Although the Australian industry is not large on 
a world scale, it plays an important role in the na-
tional economy and is integrated with the global 
industry through the presence of multinational 
companies and the trade in chemicals. The Austra-
lian industry is important in several niche areas, for 
example, explosives, pharmaceuticals and agricul-
tural chemicals. It has also benefited from a strong 
publicly funded research system. At the same time 
the industry continues to undergo the pains of ad-
justment as sectors hitherto protected by tariff bar-
riers face new tough competition from overseas. 
The industry will need to continue to change in the 
years ahead. 
To this end the Australian government in con-
sultation with industry recently released two re-
ports (Chemical and Plastics Action Agenda [22] 
and Pharmaceuticals Industry Action Agenda [23]. 
These reports set out industry goals and suggested 
actions in areas such as regulatory reform, invest-
ment and reinvestment in growth, in an attempt to 
ensure that a highly skilled workforce is available 
[22]; that Australia is positioned as a global phar-
maceuticals hub; that a globally competitive oper-
ating environment is created; and that the ability to 
commercialise research by investing in skills, and 
by fostering a positive culture, image and profile 
for growth is strengthened [23]. 
The Action Agendas reflect current industry 
policy thinking in Australia, namely that govern-
ment can contribute best by removing regulatory 
impediments, promoting the flow of information 
and skills, and ensuring that the public infrastruc-
ture permits competitive companies to emerge. 
Since the early 1980s there has been a distinct shift 
in government, away from programs of selective 
support for industry, and little to no sympathy for 
“picking winners”. 
While the Action Agendas have paid attention 
to the importance of international competitiveness 
in the industry they fall short in exploring in detail 
any of the strategies that may be available to the 
industry at large to innovate, and thus achieve a 
more competitive position. This paper addresses 
these issues in more detail, but first reviews the ex-
ternal and internal setting of the Australian chemi-
cals industry and the factors that have shaped its 
development. 
Methodology 
We have adopted an inductive, comparative 
case study approach to theory development [24]. 
This permitted new factors to be examined as they 
emerged while also allowing patterns to be com-
pared and contrasted across the cases. The case 
studies involved personal interviews by at least one 
of the researchers with senior personnel in each 
company, following a prescribed systematic for-
mat, which specifically addressed the circum-
stances relating to the development and implemen-
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tation of their innovation(s), but also permitted 
some flexibility in the discussions. In total we have 
conducted case studies on over 25 companies 
working in the chemicals sector. The choice of the 
case study approach was also motivated by our in-
terest in developing a consistent framework to 
embrace the innovation activities of these compa-
nies over time, and to monitor the achievements 
for a wide range of emerging Australian science 
and engineering based companies working in the 
chemical industry [25]. Several of the case studies 
have also formed the basis for a series of detailed 
industry profiles to inform specialists working in 
the chemical/biotechnology sector [26]. It is also 
important to note that many of the newer compa-
nies reported in this paper may be characterised as 
having advanced technology products developed 
from the R&D base, and supported by strong in-
tellectual property protection. 
The historical setting for the Australian chemi-
cal industry as a whole has been well documented 
by Kolm [27]. 
In addition to the case study approach we have 
analysed some of the dynamics of change within 
the industry sector by examining the National Ac-
counts (the industry input-output statistics) avail-
able for Australia and a number of other countries 
(the latter are not discussed) over the period of fif-
teen years from 1983-84 to 1998-99 [28]. While the 
present analysis is preliminary, it serves to amplify 
the enormous changes that have occurred in the 
chemical industry sector, especially over the period 
involving the sector’s radical transformation 
through opening up the economy to international 
competition and globalisation. 
Strategic Setting 
Evolution of the Chemical Industry in Aus-
tralia 
The chemical industry in Australia has its ori-
gins in the nineteenth century. Chemical manufac-
turing was initially directed towards meeting the 
needs of new colonies, and to support its resource-
based industries [27]. Fertilisers were needed for 
Australia’s nutrient-poor farmland, explosives for 
its mines, and processing chemicals to treat its 
mineral ores. The high cost of international freight 
meant that it was more economic to manufacture 
chemicals locally and a small but growing domestic 
manufacturing base emerged. 
The focus on local markets continued well into 
the twentieth century, supported by the high tariff 
walls and licensing arrangements that applied to 
the manufacturing sector. This situation prevailed 
after the Second World War when government 
policies supported growing “infant industries”. 
From the 1950s a number of multinational com-
panies entered Australia’s manufacturing sector, 
and expanded the ranks of the Australian chemical 
industry, which consisted of a large number of 
small and medium sized companies and just a few 
sizeable companies such as the diversified chemi-
cal producer ICI Australia (now Orica), Faulding 
Pharmaceuticals, which is now part of the Mayne 
Group and Nicholas (Aspirin), which is now 
owned by Bayer. 
While manufacturing tariff protection provided 
a cushion for the Australian chemical industry and 
secured local markets, it retarded innovation, ex-
pansion and export seeking growth. There were 
also no government incentives for innovation-
based exporting companies. A leading example is 
the integrated petrochemical complex established 
in Victoria in 1961 by a consortium of seven com-
panies, Mobil, Exxon, Dow Chemicals, Union 
Carbide, BFGoodrich, BASF and Hoechst. It was 
built to process the oil findings from Bass Strait 
and produce synthetic resins and chemicals. While 
the plant operated efficiently in the tariff protected 
environment it remained small scale by world 
standards. The failure to expand the plant to world 
scale and compete internationally meant it became 
uneconomic when tariffs were eventually reduced. 
In the 1980s the Australian government com-
menced a series of reforms to deregulate the econ-
omy and reduce tariffs. The 1986 recommenda-
tions of the Industries Assistance Commission 
were adopted and tariff barriers for the chemical 
industry progressively decreased from levels as 
high as 45 % to between zero and 5 % by 1996. 
The tariff reductions were inevitably accompanied 
by increased imports. Further, the industry had to 
deal with the problem of aging assets and sub-scale 
plants and find ways to access international mar-
kets. Today the industry continues to restructure 
to meet the demands of global competition. 
Some companies continue to be in the throes 
of adjustment, while others have made the transi-
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tion with some success. On the positive side, a 
number of new, “born-global” companies have 
been formed across parts of the industry [29]. 
The Australian Chemical Industry Today 
The chemical industry accounts for about 12 % 
of total manufacturing in Australia, with a turnover 
of about AUD 28 billion (1999-2000) and employs 
over 91,000 people [23]. In 1999-2000, 
AUD 4.5 billion worth of chemical products were 
exported and AUD 15.1 billion of chemical prod-
ucts imported – a net deficit of over 
AUD 10 billion. Australia accounts for only about 
1 % of world chemical production and is clearly a 
significant net importer of chemicals. There are 
some 3,800 enterprises operating across the full 
spectrum of the chemical industry. More than 
80 % of these are small and medium-sized busi-
nesses, each employing less than 200 people. The 
Australian industry is also geographically dis-
persed, with activity spread across the States of 
Victoria (38 %), New South Wales (34 %), Queen-
sland (12 %), South Australia (7 %), Western Aus-
tralia (7 %), and Tasmania (2 %). 
The industry is extensively linked to the global 
chemical industry as well as most of the major ‘big 
pharma’ pharmaceutical houses., through interna-
tional trade and the operations of several multina-
tional companies such as DuPont, Dow Chemical, 
Huntsman, Pfizer, Exxon Chemicals, Merck, 
Pharmacia, Bristol Myers-Squibb, Eli Lilly, Wyeth, 
Schering Plough, Bayer, BASF, Sanofi-Aventis, 
Degussa, and Boehringer-Ingelheim. There are just 
a few large local companies such as CSL, Orica, 
Nufarm, and Incitec. 
The amount spent on research and develop-
ment by the chemical industry in Australia is not 
large by international standards AUD 584 million 
in 2003-04 [30]. Of the top 50 R&D performing 
business spenders in 2002-03, 14 were in the 
chemicals sector. These companies spent over 
AUD 275 million on R&D in 2002-2003, with the 
biomedical/chemical company CSL Ltd being the 
leading performer spending more than 
AUD 90 million per annum [31]. In the related 
biotechnology sector the total R&D expenditure 
was AUD 378 million. Most of the multinational 
companies conduct R&D in Australia – indeed 
pharmaceutical multinationals rank in the top 50 
business spenders on R&D, but the expenditures 
of the multinational companies are just a small 
fraction of their global budgets. 
An offsetting factor is the expenditure on R&D 
by the public sector through universities, and re-
search institutions such as CSIRO and State agen-
cies. Australia has high public spending on R&D 
across all the manufacturing sectors. The strong 
research base is reflected in Australia’s position of 
15th in an international ranking of chemical publi-
cations with 15,682 papers published in the decade 
to August 2004 [32]. In addition, the medical and 
health related research provides a platform of sup-
port for the local chemical industry. In 2002-2003 
Australia public funded expenditure on the chemi-
cal, biological and medical and health sciences was 
AUD 3.15 billion. 
To illustrate how the chemical industry in Aus-
tralia has evolved over the past two decades we 
compare data from the Australian National Ac-
counts for 1983-84 with that of data for 1998-99, 
namely a gap of some 15 years, and one embracing 
the critical changes in micro-economic reforms. 
Australian National Accounts’, data at the 4-digit 
level provides detailed information on the inputs 
to a selected industry sector and traces these inputs 
to outputs across all sectors in the economy [28]. 
In order to provide a simplified illustration of the 
transformation of the chemical sector over the 15 
year gap we have plotted the common inputs for 
each of the chosen years against the outputs across 
all important, but aggregated, sectors of the econ-
omy, as shown in Figure 1 for 1983-84 and Figure 
2 for 1998-99. 
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Figure 1: Input/Output Data for the Chemicals Sector A - 1983-84 
Figure 2: Input/Output Data for the Chemicals Sector B – 1998-99 
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The stark changes in the contributions of the 
chemicals sector to other sectors of the Australian 
economy are shown by the changes in the magni-
tude of the peaks in these plotted matrices. For 
example, by 1998-99 the medical and pharmaceuti-
cals (human and animal) element of the sector ex-
hibited a substantial increase for exports 
~AUD 75 to ~ AUD 956 million and in uses in 
agriculture ~ AUD 152 to ~ AUD 1,447 million, 
and doubled in magnitude in the provision of 
medical services (AUD 365 to AUD 734 million). 
In contrast, the use of chemical products in agri-
culture decreased substantially from 
AUD 863 million in 1983-84 to only 
AUD 376 million in 1998-99, as did the applica-
tion of chemical products within the sector itself, 
from AUD 967 million to AUD 500 million. The 
applications of polymers (plastics) in the food, 
beverages and tobacco sector and of rubber in the 
mining sector rose from AUD 554 million to over 
AUD 1,610 million, and from AUD 124 million to 
AUD 255 million, respectively. Exports from Aus-
tralia of petroleum and coal products rose for each 
element in the sector, but most particularly for 
pharmaceuticals, and for basic chemicals from 
AUD 229 million to AUD 1,449 million. In this 
paper our intent in using the national accounts 
data in this way is to stress that the chemicals sec-
tor has transformed to one much more strongly 
driven by meeting consumer and market demands 
over the 1980s to late 1990s. 
Innovation and Industry Competitive-
ness 
Innovation 
There have been some notable successes over 
recent years and the Australian chemical industry 
appears to have lifted its innovation profile since 
deregulation (in this context success is defined by 
the commercial exploitation of ideas or continued 
operations with an increasing export profile). The 
Australian industry has long had a relatively strong 
record in support of domestic customers in the 
non-protected sectors of agriculture and minerals. 
In the case of minerals this extends to mining ex-
plosives and corresponding services to the mining 
sector, advances in minerals exploration [33], flota-
tion techniques in metal ore processing [27], and 
geochemical techniques in gold exploration [34]. 
In agriculture it includes plant and veterinary 
chemical developments [35]. And there is a long-
standing tradition in scientific instrumentation, 
which stems from the invention of the atomic ab-
sorption spectrophotometer and other instruments 
which have now reached high export penetration 
levels [26]. The industry continues to have access 
to a broad ranging public sector research base in 
chemistry – in the Commonwealth Scientific and 
Industrial Research Organisation (CSIRO), De-
fence Science and Technology Organisation 
(DSTO), Australian Nuclear Science and Technol-
ogy Organisation (ANSTO), the universities, and 
the Cooperative Research Centres (CRCs). Pub-
licly funded biomedical public research institu-
tions, the original home to nine to ten Nobel Prize 
winners, has provided the springboard for the de-
velopment of the medical and health products in-
dustry (including pharmaceuticals). More recent 
examples of innovative outcomes in the Australian 
chemical industry are provided in more detail in 
Section 5. 
In addition, an analysis of patenting activity in 
the USA for a range of OECD countries, includ-
ing Australia, independently demonstrates that 
over the period 1980 – 2001 Australia concen-
trated on slow changing technologies (having high 
technology cycle times, but with a strong focus on 
the scientific knowledge base, i.e., strong linkages 
between patents and scientific publications). This 
analysis is neatly summarised in Figure 3 [36]. 
Note that TCT was calculated on the basis of the 
average age of the patents cited, and SL on the 
number of scientific publications cited in the pat-
ent. 
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International Competitiveness 
Let us consider the return on investment in in-
novation across the chemical industry. Using R&D 
intensity (R&D expenditure/sales) as a proxy, 
Simpson et al. [37] have shown that the Australian 
chemical industry may be considered as sub-
divided into three segments or “tiers”. Further, the 
growth prospects in each segment of the industry 
can also be deduced. 
• Segment 1: The low R&D-intensity segment 
of the industry includes companies engaged in 
the production of high volume, low-value 
added products such as mineral-based inor-
ganic chemicals, petrochemicals, and bulk 
polymers. This industry segment has dimin-
ished in importance in Australia as petro-
chemical and polymer production has moved 
towards a few world-scale production facilities 
– none of which are located in Australia, this 
in spite of the sustained process innovation 
that has occurred over the years in the design 
and application of catalysts to improve process 
efficiency, and to which Australian scientists 
have made significant contributions. More-
over, this is a relatively mature segment of the 
industry. 
• Segment 2: The moderate R&D-intensity 
segment of the industry comprises companies 
manufacturing special purpose chemicals, such 
as dyes, paints, food additives, photographic 
materials, with moderate innovation expendi-
tures. Many of the products are mature and in-
volve large scale, as opposed to batch produc-
tion outputs. There continue to exist opportu-
nities for smaller companies to grow as niche 
producers or suppliers to global production 
networks, despite the presence of large interna-
tional firms in this segment. 
• Segment 3: The high R&D-intensity seg-
ment comprises companies that operate in 
high value added, low-volume chemicals. This 
includes pharmaceuticals and products from 
frontier areas of development like biotechnol-
ogy and nanotechnology. In this segment 
growth is driven by excellence and understand-
ing at the molecular level. New spin-off com-
panies from research institutions and universi-
ties contribute to this segment. 
Figure 3: Patent outcomes for a variety of countries showing the link between science link-
ages and technology cycle times [36]. 
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First we observe that globalisation of the 
chemical industry and the “commoditisation” of 
many chemicals mean that price advantages lie 
with scale economies and large, low cost opera-
tions. In the field of petrochemical processing the 
small scale and inefficient plants in Australia are 
increasingly unable to compete with large com-
plexes established in the Asian region, in countries 
like Singapore, Korea and China. Moreover, there 
are few inducements for multinational companies 
to further develop competitive size plants in Aus-
tralia following from the generally non-
interventionist industry policy approach by Austra-
lian governments. 
Second, the chemical sciences are no longer a 
strictly isolated discipline. Today it is necessary to 
address the pervasiveness of chemistry across a 
whole spectrum of activities. For example, the 
core technologies in fuel cells are electrochemistry 
and catalysis and such activities stand to revolu-
tionise the transport industry, not the chemical 
sector. Companies in the industry have the oppor-
tunity to explore more ways to use their knowl-
edge assets, e. g. in the way they deliver their 
product line, manage their intellectual property, or 
operate across a wider section of the industry value 
chain [38]. 
Third, the growing importance of partnerships 
and collaboration are evidenced by the surge in the 
growth of R&D and technology based alliances 
across the globe in recent years. This has become 
particularly significant over the past decade in the 
area of pharmaceuticals. It is generally acknowl-
edged that Australia does not possess the re-
sources necessary to take a new exploratory drug 
compound through the maze of phases and ap-
provals necessary to bring such an advanced prod-
uct to market. As a consequence, Australian busi-
nesses have been quick to realise the need to net-
work and form alliances with the major pharma-
ceutical houses. Some successes have been 
achieved and there are many more in the pipeline 
where the alliance strategy must become second 
nature. In turn, such a strategy demands that the 
source of the idea (in Australia) must have strong 
intellectual property rights in order to gain the 
complete advantage from commercialisation. The 
growth in strategic alliance formation both within 
and external to Australia accelerated Australia to 
number one in the world in the number of alli-
ances formed on a per capita basis [39]. 
Lessons from Experiences 
In pursuing the case study approach we have 
examined in detail the innovation experiences of a 
range of successful companies and sought to de-
termine their common behaviours in order to seek 
wider insights into current innovation processes 
within the Australian chemical industry. In addi-
tion we have drawn on the findings of the two 
Government Action Agenda Reports [22, 23], and 
on the experiences of other industry contacts. A 
number of important generalisations emerge from 
this collective information – notably the ingredi-
ents for the successful sustainability of Australian 
firms in the chemical industry. 
The data reveal a considerable shift in the 
mindset within the Australian chemical industry, 
arising primarily from recognition of the need to 
focus on wider global markets. The successful 
companies demonstrated that their positioning in 
the international industry “system” was critical, 
and many made these moves to internationalise 
early in their development phase – the born-global 
companies [29]. Internationalisation not only un-
derpins companies’ networking and relationship 
building, but also the way in which they develop 
their knowledge base and capabilities. Successful 
innovation is clearly associated with: 
1. working within the industry value chain, 
2. engaging in the global value chain of other     
industries. 
A related but distinct theme is “leveraging 
knowledge from others”, especially in product de-
velopment and in the process of marketing. This 
emerged from the case studies as an important 
phenomenon. It is consistent with the views of 
Chesborough on “open innovation” or drawing on 
external sources for ideas, e. g. from other compa-
nies through research or technology alliances or 
from public sector research institutions [20]. We 
consider that the formation of new companies 
from the public or private sector fall into these 
categories since “spin-offs” most frequently in-
volve licensing the technology from a parent com-
pany or a research institution. 
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In summary, the two additional innovation 
strategies adopted by Australian chemical compa-
nies to attain a world competitive position in the 
chemicals sector in the post-protectionist era have 
been: 
3. developing an integrated packaging concept 
for their products and services, and 
4. leveraging the knowledge of others. 
Other authors [39, 40] have referred to “lever-
aging the knowledge of others” in the broader 
sense as “systems integration” – combining the 
best from the world stable of innovative solutions, 
and creating from the combinations a unique and 
new product, system or service [29, 39]. 
Each of these mechanisms is illustrated in the 
next Section with reference to a cross section of 
case study examples. 
Innovation Strategies 
Working Within Existing Global Value 
Chains 
The pharmaceuticals industry is a global value 
chain dominated by just a few large pharmaceutical 
houses. Each stage of the innovation process is a 
separate market within the overall pharmaceuticals 
market. At each stage value is added, innovation 
takes place, resources are used and people are em-
ployed. One of the consequences of globalisation 
in this industry is that companies choose the loca-
tion of their activities at each stage according to 
the perceived benefits. This creates opportunities 
for companies across the globe to contribute at 
various stages of the global chain activities. 
The pharmaceuticals industry is the highest-
growth and highest profitability segment of the 
chemical industry. It is an innovative knowledge-
based segment with high R&D intensity, and a 
skilled workforce. While not large on an interna-
tional scale, Australia makes significant invest-
ments in the development of a local pharmaceuti-
cals industry - the human pharmaceutical industry 
is reported to have had a turnover of 
AUD 3.7 billion in 2001, a workforce of 8,400 
people. Exports represented over AUD 1.4 billion 
[23]. 
The industry in Australia has also been sup-
ported by a series of federal government programs 
in recent decades. These draw on the leverage 
available through the Pharmaceuticals Benefits 
scheme to provide offsets in pricing against com-
mitments to research and development, manufac-
ture and exports. Thus the first of these – the Fac-
tor f program was introduced in 1988, and modi-
fied versions of this incentive have followed, in-
cluding the PIIP program in 1999 and then the P3 
program in 2004. Under the Factor f program 
there was a marked increase in R&D in Australia, 
and this led to a strong and growing position in 
discovery research. Australian capacity in clinical 
development grew under the influence of the later 
programs, but there has been limited net effect on 
investment in manufacture [23]. However, Austra-
lia has strengthened its position in recent years in 
the research-based identification and preparation 
of new chemical entities. The industry view is that 
this was directly influenced by government pro-
grams, notably the former Factor f program. This 
provides an opportunity for Australian endeavour 
to contribute to the international industry and to 
secure a position in the global value chain. Austra-
lia’s capacity for conducting clinical trials also in-
creased with the development of new facilities. 
The well known drug development “funnel” 
for human pharmaceutical production emphasises 
that there may be many target/discovery drugs, 
but only a few make the grade through the process 
to market. Drug discovery has traditionally been 
focussed on large scale assaying of chemicals from 
natural sources, but increasingly this approach is 
being complemented by the design and molecular 
synthesis of drugs on a more targeted basis. In ad-
dition, combinatorial chemical techniques have be-
come common-place in academic research, but are 
not as yet frequently used in the pharmaceuticals 
industry. Australian software developments 
(chemometrics) provide a mechanism for the iden-
tification of lead compounds from the complex 
mixtures involved (Scimetrics Ltd. and CSIRO) 
[41]. The interest of the ‘big pharma’ companies is 
in drawing on fresh streams of research, often 
stemming from the public sector research institu-
tions as a source of new chemicals for testing. The 
manufacturing and marketing phase comprises 
four steps: the synthesis of the basic chemicals, the 
high value-adding step of manufacturing active in-
gredients, formulation, and finally packaging and 
distribution. 
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The ‘big pharma’ operate across the full value 
chain, but there are also “safety gates” to interna-
tional markets, including the US Food and Drug 
Administration (FDA). Successful drugs can 
achieve global markets of two or more USD bil-
lion dollars per year, but the path to success is nar-
row. The number of new chemical entities (these 
are the active ingredients which deliver the thera-
peutic benefit) finally cleared to enter the market is 
small, just 20 new chemical entities received FDA 
approval in 2004. 
Australia has a few pharmaceutical manufactur-
ing plants mainly involved in formulation and 
packaging, bolstered recently by GlaxoSmith-
Kline’s decision to manufacture Relenza™ in Aus-
tralia. Basic chemical production is generally done 
in low cost countries like India and China; the ac-
tive pharmaceutical ingredient (the main value add-
ing step) is mostly done in countries that offer tax 
advantages like Ireland, Puerto Rico and Singa-
pore. The subsequent steps of formulation and 
packaging are low value adding and can be done 
anywhere. 
The big pharma companies generally choose to 
take most of their profit into the country in which 
they manufacture the active pharmaceutical ingre-
dients. There has been a migration of production 
capacity to Singapore in recent years in response to 
tax incentives and subsidies. Over AUD 2.5 billion 
dollar has been spent on new plants by Merck, 
Sanofi-Aventis, GlaxoSmithKline, Wyeth and 
Pfizer, but until very recently there was no compa-
rable investment in Australia for a decade. Austra-
lia does have the capacity for small contract manu-
facturing at IDT, in radiopharmaceuticals at AN-
STO, and in the extraction of alkaloids at a small 
number of research companies. 
Specific Australian Developments in 
Pharmaceuticals 
IDT: The Institute of Drug Technology Austra-
lia (IDT), based in Melbourne with an annual 
turnover of about AUD 21 million, has secured a 
successful niche in the high-value added stage of 
manufacturing active pharmaceutical ingredients 
.When IDT commenced operations in 1986 it 
provided analytical and other services to the 
pharmaceutical industry. IDT now manufactures 
active pharmaceutical ingredients for clients from 
many countries, and conducts the entire post-
discovery pharmaceutical life cycle. That is, IDT 
can take a new chemical entity from the laboratory 
scale to full-scale production, including the con-
duct phase I - IV clinical trials. There is a trend for 
pharmaceutical companies to outsource some or 
all of their research and development and clinical 
programs. IDT built a business around this grow-
ing trend, and its success is based on the strategy 
of achieving and maintaining the highest levels of 
quality, the latter by meeting international Good 
Manufacturing Practice (GMP) standards. IDT’s 
quality systems were designed to exceed all inter-
national regulatory requirements and passed scru-
tiny from various regulatory bodies, including the 
US FDA. 
CSL Limited [26] is another Australian company 
which operates across the full value chain, al-
though this is mainly in the niche areas of plasma 
products and immunotherapy. CSL is the one 
company in Australia that is vertically integrated 
and active in all points of the value chain with a 
coherent R&D strategy in the area of immuno-
therapy. CSL’s strategy has involved major acquisi-
tions that have placed the company in a dominant 
position in blood collection and blood plasma 
processing in many international markets. The 
CSL group currently has an annual turnover of 
about AUD 2.8 billion, and has major facilities in 
Australia, Germany, Switzerland, the USA and Ja-
pan, and a staff of 7,000 employees working in 
more than 25 countries. 
Biota Holdings [26] is one of a very small group 
of companies worldwide that have brought bio-
technology medicines from research to commer-
cialisation. For other Australian companies the 
business opportunity in the discovery phase is the 
generation of new chemicals through research as 
candidates for further testing and evaluation by the 
‘big pharmas’. The level of eventual success is low 
given the small number of chemicals that make it 
through the extended testing and approval proc-
ess. The innovation strategy adopted by Biota in-
volves the formation of strategic alliances on the 
back of a strong intellectual property portfolio of 
drug compounds. Biota is currently active in at 
least three additional alliances in Japan and the 
USA. 
As a note of caution, of the success stories of 
bringing drugs from the discovery phase into in-
ternational markets, only the Biota product Re-
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lenza™, and the colony stimulating factor (CSF) 
hormone cancer medical product based on re-
search at the Walter and Eliza Hall Research Insti-
tute have so far made the grade; and it is only the 
recent scare and resultant drug stockpiling that has 
led to the manufacture of Relenza™ in Australia. 
However, in neither of the successful drug cases is 
a significant part of the value chain owned in Aus-
tralia. 
Thus, Australian companies also need to find a 
way of leveraging their discovery capability so that 
the nation owns a larger slice of the value chain. 
The challenge is to focus on those parts of value 
chain where the local industry can become among 
the best in the world and build mutually beneficial 
partnerships. Opportunities for greater efficiency 
lie in sharing resources, bringing companies of 
sub-critical size together, and mobilising the public 
R&D needed to capture more value in the global 
value chain. 
Engage in the Global Value-Chain with 
Other Industries  
As mentioned above, the chemical sciences are 
pervasive and contribute significantly to the 
growth of other international industries – e. g. 
minerals, agribusiness, health products, transport 
and printing. The minerals and agribusiness sec-
tors are leading export sectors for Australia and 
leading edge users for new and improved tech-
nologies. The leading sectors in manufacturing 
also offer opportunities for inputs from the 
chemical industry. 
For example, polymers are integral to many 
products produced for export. There are opportu-
nities for Australian companies to play a role as 
part of the supply chains for such industries. An 
example is the automotive industry which has high 
level requirements for a range of polymer compo-
nents (which account for up to 8 % of car body 
weight) with each of the major car companies 
based in Australia having a select set of specialty 
suppliers. The situation is replicated with other ex-
port industries producing products which involve 
polymer components – the opportunity exists for 
small and emerging companies to build specialist 
roles and supply high quality products to meet 
demanding specifications. Examples also arise in 
the medical and scientific equipment area – com-
panies such as Resmed, Sola and Cochlear require 
and use polymeric components produced to the 
most exacting standards. 
There may also be opportunities for customer 
driven processes involving the public sector re-
search agencies. 
Specific Australian Developments 
Plastic bank note technology: now in use in Austra-
lia and exported to many countries around the 
world was the outcome of a process initiated by 
the Reserve Bank and brought to fruition by re-
searchers in the CSIRO Division of Chemicals and 
Polymers and Note Printing Australia. The work 
involved the development of a novel polymer sub-
strate and the incorporation of a number of anti-
counterfeiting devices. 
Ciba Vision and Novartis: launched on world 
markets the day/night contact lens in 2001. This 
product emerged from a collaboration involving 
the University of New South Wales and the 
CSIRO (in the Vision CRC). 
Moldflow Corporation: Although now headquar-
tered in the USA, Moldflow was founded in 1978 
in Melbourne, as a spin-off from the Royal Mel-
bourne Institute of Technology and continues to 
have major development capability in Melbourne. 
Moldflow's software solutions have brought prom-
ise of "better, faster, cheaper" plastic products to 
major companies in various industries around the 
world. Designs for molds and products ranging 
from toys to automotive and aerospace compo-
nents to medical parts and many others were simu-
lated and optimised prior to production, saving 
manufacturers hundreds of thousands of dollars 
every year. Such solutions enable customers to 
predict and solve injection molding manufacturing 
problems in the earliest stages of product devel-
opment. 
Australia maintains a valuable core capability in 
polymer research and this should provide a plat-
form for moving to the next generation of poly-
mer products. The shift in the polymer research 
thinking is toward tailoring the properties of the 
polymer to meet the specific needs of the product. 
This entails a shift from managing the bulk prop-
erties of the polymer to managing molecular prop-
erties, and building science into the polymer. That 
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is, chemically adapting properties to make the 
polymer useful for specific end uses. Some future 
typical examples might include a range of biocom-
patible polymers, polymers designed for controlled 
release of pharmaceuticals, and polymers for appli-
cations in human tissue engineering. 
Developing an Integrated Packaging Con-
cept for Goods and Services 
It is not so long ago that chemical companies 
had no other thought than to make chemicals to 
sell to the next company in the value chain. This 
business model was built on the belief that the best 
assets (plants) would deliver the best value. How-
ever today, chemical companies must rethink 
where and how they compete. We can see some of 
these changes in the way that the Australian com-
pany Orica has integrated its explosives business 
into a suite of “mining services” and also in other 
chemical operations in Orica’s “water care busi-
ness”. The need to think differently about the way 
products, and the knowledge associated with them, 
are sold in itself entails innovation [38]. 
This involves building on existing strengths and 
drawing on knowledge from other companies and 
from other fields and offering a new “package”; 
and subsequently delivering valuable new products 
and services. The value added here is in integration 
and product and service delivery, rather than the 
manufacture of individual components. 
Specific Australian Developments 
APS Plastics is a small Melbourne based na-
tional-award winning firm which delivers high 
quality solutions through systems integration. The 
company provides polymer engineering and design 
services in the areas of plastics and polymers and 
has achieved success in areas as diverse as the co-
ordination and delivery of plastic seats for the Lis-
bon football stadium for the 2004 European Cup 
and retractable plastic syringes. It brings together 
the engineering product development, the selec-
tion and design of the polymer, the robotics and 
assembly, equipment manufacture, and manufac-
ture of the product, drawing in specialist contrac-
tors for specific projects. The company has dem-
onstrated that it is able to compete internationally 
at the top of the market with a price advantage. 
Opportunities exist in Australia for companies 
such as APS Plastics to capture markets by draw-
ing on the assorted skills and expertise available in 
the industry. John Petschel, CEO of APS talks of 
“the need to be global and brutal through estab-
lishing agility and performance using excellent 
people, effective project management, and in 
competitive tendering” [25]. 
Orica is a publicly owned Australian company 
with about 9,000 employees in 36 countries and an 
annual turnover of about AUD 4 billion. Formerly 
ICI Australia, the company grew in the 1950s and 
60s under high tariff protection. In the 1990s it 
was reconstituted as an Australian company and a 
number of its operations were sold off as part of a 
streamlining process. The businesses divested in-
cluded several polymers and related chemicals 
(PVC, ethylene, polyurethanes), technical paints, 
and crop protection chemicals. Orica now special-
ises in four areas – mining services (explosives), 
consumer products (paints and horticultural prod-
ucts), agriculture (mainly fertilisers), and industrial 
chemicals. 
Explosives provide a good example of rethink-
ing the business and leveraging knowledge. Orica 
has a long tradition in the relatively mature field of 
explosives, and a close association with the mining 
industry. Explosives were selected by Orica’s first 
CEO as a target for growth as an international in-
dustry. Several international explosives business in-
terests were acquired and the “package” of goods 
and services offered by Orica expanded. The ex-
plosives themselves are the core of the integrated 
blasting service, which also includes initiating sys-
tems, detonators, mobile manufacturing units, and 
GPS-based site management. Since 1997, Orica 
has become the world’s leading supplier of com-
mercial explosives and fully integrated blasting 
services to the mining, quarrying and construction 
industries. It has manufacturing operations in 28 
countries including China, India, Indonesia, Malay-
sia, Myanmar, Philippines, Papua New Guinea, 
Singapore and Thailand. 
Leveraging the Knowledge of Others 
There is a plethora of Australian public sector 
research institutions which are involved in research 
in the chemical and biotechnological sciences, all 
relevant to present and future industrial develop-
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ment. The list is far too large to be considered in 
the present paper. Some outcomes can include the 
commercialisation of the research by an existing 
company, or licensing the technology to provide a 
revenue stream in the form of Royalty payments, 
or alternatively to generate new spin-off compa-
nies. Some examples follow: 
Specific Australian Developments 
Boron Molecular is a new, small company with a 
narrow product line. It was established in 2000 as a 
spin-off company from CSIRO, based on novel 
organoboron technology developed in the 1990s 
by Dr. Seb Marcuccio. It is now wholly owned by 
Xceed Biotechnology Ltd. Organoboron com-
pounds are employed by a wide variety of large 
companies in their drug discovery programs. There 
was also a market for the new range of organobo-
ron chemicals in the biotechnology industry and 
for direct sale to fine chemicals companies. The 
company underwent the “test by fire” of many 
new companies – with problems in establishing 
laboratory facilities, cost overruns and over-
optimistic financial projections, but it has already 
established a business equating to several million 
dollars a year in selling its product on international 
markets. The establishment of a US office eased 
some, more perceived than real, difficulties of 
dealing with a supplier at an extended distance.  
GBC Scientific [26]: Research at the CSIRO Di-
vision of Applied Physics provided GBC with the 
opportunity to further develop for the market an 
instrument now known as the MFC 2100 Micro 
Fourier Rheometer, which can perform analyses 
on volumes of less than 100 µL on samples like 
paints, adhesives, or on human tears. GBC manu-
factures and exports a broad range of scientific in-
struments, including atomic absorption spectro-
photometers. 
Starpharma Pty Ltd. [26] was established in 1996 
to commercialise dendrimer technology discovered 
at the former Biomolecular Research Institute 
(BRI) Ltd. in Melbourne involving the synthesis of 
several biologically active dendrimers as protein 
mimics for pharmaceutical applications, in particu-
lar, for treating a broad range of viral and other 
human diseases, notably those that are sexually 
transmitted. Specifically, Starpharma developed the 
first dendrimer-based vaginal microbicide 
VivaGel™, which offers early hope that nanoscale 
dendrimers could be developed as new drug deliv-
ery platforms. 
This drug is aimed at preventing transmission 
of a broad spectrum of sexually transmitted dis-
eases (STDs) including HIV, herpes, chlamydia 
and human papilloma virus. In the USA alone, 
STDs including genital herpes affect more than 70 
million people annually. It was estimated in 1999 
that the annual cost of all STDs was more than 
USD 10 billion a year. 
All of the above examples are of born-global 
companies, since they all entered the international 
arena almost at the point of their conception [29]. 
There are also opportunities for companies to 
work collaboratively with public research organisa-
tions on projects with agreed shared objectives and 
to draw on these sources of expertise. Collabora-
tion with industry partners has been a growing fea-
ture of research conducted by CSIRO and other 
public research institutions including universities. 
It is also a core feature of the seventy or so Coop-
erative Research Centres which operate across the 
research spectrum. The value of this approach is 
exhibited in the success of Hawker de Havilland 
(HdH), a long standing core industry participant in 
the CRC for Advanced Composite Structures. Re-
search conducted by the CRC and transferred to 
HdH was essential to the company’s recent suc-
cess in winning the contract to construct all the 
wing trailing edge devices, including flaps, spoilers 
and ailerons on the new Boeing 787 [42]. 
Outlook 
We have drawn some general lessons by re-
viewing the common elements in successful inno-
vation case studies of more than 25 companies op-
erating in the Australian chemical industry, follow-
ing the deregulation and globalisation phenomena 
that have characterised the industry over the past 
one to two decades. 
First, it is evident from the information on 
R&D intensity that the prospect for Australia to 
develop a position as a major player in Segment 1 
of the industry - the area of production of bulk 
chemicals is negligible in the event that the major 
players do not invest in the near-term in large-scale 
processing plants in Australia. 
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Second, Segment 2 products are generally built 
around speciality chemicals, which do not neces-
sarily demand high research intensity and the op-
portunities for Australia to make a significant mark 
on the world scene appears low and possibly re-
ducing. Most of the products in Segments 1 and 2 
of the industry are mature and for cost efficiencies 
to be gained these demand large scale processing. 
Where Australian companies may succeed in Seg-
ment 2 may involve yet to be identified opportuni-
ties in novel customer-driven batch production. 
Third, future success in the Australian chemical 
industry clearly depends on Australia’s capacity to 
change through innovation, either by drawing on 
its own high quality research base, or alternatively 
integrating capabilities from other sources. This 
approach is justified by the outcomes of the case 
studies. 
We conclude that the lessons to be learned 
from the case studies for future opportunities in 
the chemicals sector must rest on at least the pur-
suit of four simple mechanisms of innovation 
drawn from the case studies. These “innovation 
strategies” include existing and new players (1) 
working within existing global value chains, (2) en-
gaging with other globally focused industries, (3) 
developing an integrated packaging concept for 
their products and services and (4) leveraging the 
knowledge of others. 
In other words, the evidence suggests that the 
preferred mechanism for sustained development 
of an Australian identity in the chemicals sector 
will best be achieved through the adoption of 
niche strategies. Australia cannot afford to be 
complacent about its “chemical future”. The task 
at hand is an urgent one, and the urgency is for 
Australian industry to be more innovative in order 
to ensure its future global competitiveness. 
From a policy perspective, we suggest that the 
most important lesson is that the chemical sector 
should not be considered as the conglomerate that 
statistical data collections have tended to impose 
on the analyses, but rather as a series of distinctly 
different components such as those delineated by 
the segmental analysis. There is a need to nurture a 
well connected and relevant research base, from 
which entrepreneurs and companies can be born 
with the agility and foresight to capture the oppor-
tunities that arise. Not only that, but government 
policies should aim to provide a supportive envi-
ronment for the growth of new and emerging born 
global companies, and new born global activities 
taken up by existing companies. 
We suggest that the strategies for innovation 
that emerge from this study are also applicable to 
any small country that is unlikely to be the subject 
of major foreign investments in the manufacture 
of bulk or special purpose chemicals, but which 
possesses a strong research infrastructure. 
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